NCT01469130View on ClinicalTrials.gov

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

February 1, 2018

Conditions
Advanced Solid Tumor
Interventions
DRUG

MEK162

MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).

Trial Locations (2)

466-8560

Pfizer Investigative Site, Nagoya

879-5593

Pfizer Investigative Site, Yufu

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01469130 - A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter